Mark Douglas Smith Sells 7,000 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) Director Mark Douglas Smith sold 7,000 shares of the company’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $25.00, for a total value of $175,000.00. Following the sale, the director now owns 30,653 shares of the company’s stock, valued at approximately $766,325. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Phreesia Stock Performance

Shares of NYSE PHR opened at $23.84 on Thursday. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -10.99 and a beta of 0.93. Phreesia, Inc. has a one year low of $12.05 and a one year high of $32.11. The business has a fifty day simple moving average of $21.28 and a 200 day simple moving average of $23.10. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.03.

Phreesia (NYSE:PHR) last issued its earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.16. Phreesia had a negative net margin of 31.87% and a negative return on equity of 46.89%. The business had revenue of $101.20 million for the quarter, compared to analyst estimates of $100.94 million. During the same period in the previous year, the business earned ($0.70) EPS. The firm’s revenue was up 20.8% on a year-over-year basis. Sell-side analysts expect that Phreesia, Inc. will post -1.16 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PHR shares. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Friday, May 31st. Stephens reaffirmed an “overweight” rating and set a $28.00 price objective on shares of Phreesia in a report on Friday, May 31st. KeyCorp decreased their price target on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Canaccord Genuity Group dropped their price objective on Phreesia from $37.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 31st. Finally, JMP Securities restated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Friday, May 31st. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $30.54.

Institutional Investors Weigh In On Phreesia

Several large investors have recently modified their holdings of the stock. Raymond James & Associates bought a new stake in shares of Phreesia during the fourth quarter worth $226,000. Raymond James Financial Services Advisors Inc. increased its stake in Phreesia by 18.5% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 17,927 shares of the company’s stock worth $415,000 after purchasing an additional 2,805 shares in the last quarter. Trust Point Inc. acquired a new stake in shares of Phreesia during the fourth quarter worth $239,000. WoodTrust Financial Corp acquired a new stake in shares of Phreesia in the 4th quarter valued at about $382,000. Finally, International Assets Investment Management LLC raised its position in Phreesia by 1,987.3% in the 4th quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock valued at $34,000 after buying an additional 1,411 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.